Research programme: antiviral compounds - Anadys/Gilead

Drug Profile

Research programme: antiviral compounds - Anadys/Gilead

Alternative Names: Antiviral compounds research programme - Anadys/Gilead; CDK inhibitors research programme - Anadys/Gilead; Cyclin-dependent kinase inhibitors research programme - Anadys/Gilead

Latest Information Update: 20 May 2008

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Anadys Pharmaceuticals; Gilead Sciences
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Viral infections

Most Recent Events

  • 19 Jun 2006 No development reported - Preclinical for Viral infections in USA (unspecified route)
  • 20 Feb 2004 Data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the Viral infections pharmacodynamics section
  • 19 Jun 2002 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top